Indian scientists develop a new method to synthesize antibody-drug conjugates (ADC) using the chemical route. ADCs combine drugs with antibodies that specifically target tumour markers in cancer cells. When administered to patients, antibodies in a conjugate track tumour markers and attach themselves to the surface of cancer cells.
Bhopal (ISW) – In a promising development in the area of targeted treatment of cancer, a team of researchers at the Indian Institute of Science Education and Research (IISER), Bhopal, have developed a new method to synthesize antibody-drug conjugates (ADC) using the chemical route.
Antibody-drug conjugates combine drugs with antibodies that specifically target tumour markers in cancer cells. When administered to patients, antibodies in a conjugate track tumour markers and attach themselves to the surface of cancer cells. The antibody-marker reaction triggers a signal in tumour cells which absorbs antibodies together with the drug.
However, the difficulty is that several amino acid residues in antibodies like lysine, tyrosine, tryptophan, cysteine, and histidine compete during installation of drugs. Amino acid residues also have multiple copies, each having different level of reactivity making it difficult to identify the right one.
The researchers at IISER have now demonstrated that it was possible to synthesize an effective conjugate with lysine without much of a problem. The process makes use of 4-acetylbenzaldehyde, an electron-rich aromatic aldehyde and triethylphosphite, which is an organo-phosphorous compound used as a reagent.
“We had earlier demonstrated that it was possible to differentiate various copies of lysine for level of reactivity and to selectively pick up the desired one, but we still could not develop a conjugate as we had used a metal-complex. Now the reaction is metal-free. A sequential formation of C-N bond and a C-P bond results in the labeling of lysine which is followed by installation of the drug,” explained Dr. Vishal Rai, leader of the team.
The team has developed conjugate of breast cancer drug, Trastuzumab, and anti-cancer drug Doxorubicin and tested its anti-proliferative effect on a HER2 over-expressing cancer cell line. After two days of treatment, the conjugate showed significant inhibition of SKBR3 breast cancer cell proliferation. For evaluating selectivity of the conjugate, the researchers compared its anti-proliferative effect against a direct dose of Doxorubicin for effect on SKBR3 breast cancer cells and on the non-pathogenic HER2 negative MDA-MB-231 cells.
“The anti-proliferative activity towards breast cancer cells holds promise for further pre-clinical evaluation,” commented Dr. S. Chandrasekaran from Indian Institute of Science, Bangalore, who was not associated with this study. Dr.T. Govindaraju from Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, said, “specific advantage of this bio-conjugation technique is that it is metal-free.”
The technology is being transferred for commercial use through the IISER Bhopal based startup, Plabeltech. The results of the study, funded by the Science and Engineering Research Board (SERB), were published in journal Chemical Communications.
